中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2013年
8期
618-623,636
,共7页
乳腺肿瘤%趋化因子%非典型性趋化因子受体
乳腺腫瘤%趨化因子%非典型性趨化因子受體
유선종류%추화인자%비전형성추화인자수체
Breast tumor%Chemokines%Atypical chemokine receptors
趋化因子参与乳腺癌细胞的生长、血管生成及远处转移过程。然而，近年来单靶点趋化因子受体拮抗剂的临床试验多以失败告终，彰显了肿瘤微环境中趋化因子网络的复杂性，因此基于多向药理学原理确立多靶点调控策略势在必行。多靶点非典型性趋化因子受体(ACR)作为内源性和生理性的调节分子，有可能成为捕获高表达的多种促肿瘤性趋化因子、有效控制乳腺癌的利器。
趨化因子參與乳腺癌細胞的生長、血管生成及遠處轉移過程。然而，近年來單靶點趨化因子受體拮抗劑的臨床試驗多以失敗告終，彰顯瞭腫瘤微環境中趨化因子網絡的複雜性，因此基于多嚮藥理學原理確立多靶點調控策略勢在必行。多靶點非典型性趨化因子受體(ACR)作為內源性和生理性的調節分子，有可能成為捕穫高錶達的多種促腫瘤性趨化因子、有效控製乳腺癌的利器。
추화인자삼여유선암세포적생장、혈관생성급원처전이과정。연이，근년래단파점추화인자수체길항제적림상시험다이실패고종，창현료종류미배경중추화인자망락적복잡성，인차기우다향약이학원리학립다파점조공책략세재필행。다파점비전형성추화인자수체(ACR)작위내원성화생이성적조절분자，유가능성위포획고표체적다충촉종류성추화인자、유효공제유선암적이기。
Many chemokines and chemokine receptors, such as CCL2 and CXCR4, participate in the growth, angiogenesis, distal metastasis of breast cancer. However, the recent failures in the clinical trials of some single target antagonists suggest that chemokine network in tumor microenvironment is really complicated. Obviously, multi-targets regulation strategy for chemokines is indispensable based on the polypharmacological principle in the future. Atypical chemokine receptors (ACR) as endogenous and physiological regulators, including Duffy antigen receptor for chemokines (DARC), D6 and ChemoCentryx chemokine receptor (CCX-CKR), may be the powerful candidates for this purpose.
